Two Thousand Seven Highlights
Quarter Four Highlights
Re-purchased approximately 537,000 shares of Beckman Coulter stock at an average price of $69.71 per share, completing the company’s 2.5 million share repurchase authorization.
Signed agreements with Johns Hopkins University, a leader in cancer genomics research, that provide Beckman Coulter exclusive options to license cancer genomics intellectual property that arise from its studies of multiple types of cancer including breast, colon and six others.
Acquired the remaining 80.1% of NexGen Diagnostics LLC gaining control to technologies with the potential to greatly simplify future immunoassay and molecular diagnostics testing.
Acquired the flow cytometry business of Dako Denmark AS, significantly broadening Beckman Coulter’s research flow cytometry product line offering.
Renewed agreements valued at approximately $94 million per year with MedAssets Supply Chain Systems, one of the nation’s largest healthcare group purchasing organizations, serving more than 125 health systems, including 2,500 hospitals.
Entered into a two-year research project to be carried out at Thomas Jefferson University, Philadelphia and Laboraf Diagnostica e Ricerca San Raffaele SpA in Milan, Italy. Research will seek to discover genetic signatures for cardiovascular disease (CVD) and obesity-related hypertension, which would yield exclusive proprietary content for Beckman Coulter’s molecular diagnostics system.